What the science says about GLP-1s and muscle
GLP-1 medications work. They also do something the scale hides: a meaningful share of the weight you lose can come from lean mass — muscle — not just fat. Here's the current evidence, and the two habits that protect your strength.
1. Some of the weight is muscle
Across recent trials and systematic reviews, roughly a quarter to 40% of the weight lost during GLP-1 treatment comes from lean tissue rather than fat. In the STEP-1 semaglutide trial, lean mass fell about 9.7% while fat mass fell about 19.3% at ~15% total weight loss.
The scale says "success." Your legs on the third flight of stairs may disagree. That gap is muscle.
2. It is not inevitable — this is the good news
Muscle loss during weight loss is heavily influenced by what you do, not just the drug. The American Council on Exercise (2025) concluded lean-mass change is driven more by protein intake and resistance training than by the medication itself. A 2025 program pairing GLP-1s with resistance-training education and individualized protein saw ~13% weight loss but only ~3% muscle loss.
3. The two levers
- Protein. Consensus for muscle preservation during weight loss is roughly 1.2–1.6 g per kg of body weight per day (well above the 0.8 g/kg RDA), spread across 3–4 feedings. Find your number →
- Resistance training. Just 2–3 short sessions a week of compound movements is enough to signal your body to keep the muscle. No marathon gym sessions required.
A quick caveat we take seriously: high-protein eating is safe for healthy kidneys, but if you have advanced kidney disease, individualization matters — talk to your clinician.
4. The part after the drug: keeping it off
Most content stops at "lose the weight." But a large share of people regain weight after stopping a GLP-1 — driven by returning appetite and a lower metabolic rate. Keeping the protein-and-strength habits above through and beyond any step-down is associated with less rebound. That's why our meal plans change across Loss, Taper, and Maintenance.
What we're honest about
There are still no large trials specifically in trained, athletic GLP-1 users — today's guidance is a careful synthesis of mechanistic reasoning and adjacent clinical data. We state that plainly rather than overselling certainty — treat every number here as a guideline to adapt to your own situation.
Sources
- STEP-1 body-composition analysis — lean vs. fat mass on semaglutide.
- American Council on Exercise (2025) — GLP-1s and lean mass.
- Systematic reviews on lean-mass loss during GLP-1-RA treatment (2025).
- Consensus protein guidance for weight-loss muscle preservation (1.2–2.0 g/kg).
- GLP-1 discontinuation & weight-regain analyses (eClinicalMedicine, 2026).